Topical Drug Delivery Market - Global Forecast To 2030
商品番号 : SMB-16029
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年8月 |
| ページ数 | 435 |
| 図表数 | 539 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
本レポートは、局所薬物送達市場を分析しています。製品、適用部位、エンドユーザー、地域といった様々なセグメントに基づき、市場規模と将来の成長ポテンシャルを推定することを目的としています。また、市場で入手可能な様々な局所薬物送達製品の製品ポートフォリオマトリックスも掲載しています。さらに、主要プレーヤーの競合分析に加え、各社の企業概要、製品ラインナップ、主要な市場戦略についても提供しています。
The global topical drug delivery market is expected to reach USD 409.0 billion by 2030 from USD 268.4 billion in 2025, at a CAGR of 8.8% during the forecast period. The growth of this market can largely be attributed to the uptake of topical prescription therapy for dry eye diseases, the growing focus of pharmaceutical companies on the R&D of innovative transdermal drug delivery systems, the increasing prevalence of skin infections, and the rising preference for non-invasive drug delivery methods.
世界の局所薬物送達市場は、2025年の2,684億米ドルから2030年には4,090億米ドルに達し、予測期間中に8.8%の年平均成長率（CAGR）で成長すると予測されています。この市場の成長は、ドライアイ疾患に対する局所処方薬の普及、製薬会社による革新的な経皮薬物送達システムの研究開発への注力、皮膚感染症の増加、そして非侵襲性薬物送達法への関心の高まりに大きく起因しています。
By product, the semi-solid formulations segment accounted for the largest market share in 2024.
By product, the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other products. The large share of the semi-solid formulations segment is attributed to enhanced patient adherence with limited side effects, high absorption, and efficient provision of drug release. These dosage forms are non-dehydrating and do not modify skin functioning, fueling market growth.
By site of application, the dermal drug delivery segment accounted for the largest market share in 2024.
By site of application, the market is segmented into dermal drug delivery, ophthalmic drug delivery, rectal drug delivery, vaginal drug delivery, and nasal drug delivery. The large share of the dermal drug delivery segment can be attributed to the increasing product launches in the market. Fewer regulatory requirements and lower irritation than nasal or ophthalmic drug delivery also contribute to market growth. Dermal drug delivery through nanoemulsions is also suitable for chronic and autoimmune diseases, such as psoriasis and vitiligo.
By region, North America accounted for the largest market share in 2024.
By region, North America accounted for the largest share of the market in 2024. The large share of this region is attributed to the high risk of skin disorders, the rising prevalence of chronic diseases (such as diabetes), increasing use of contraceptives, the increasing geriatric population, and the growing focus of pharmaceutical companies on the R&D of innovative transdermal drug delivery systems.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
- By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)
Breakdown of demand-side primary interviews:
- By Company Type: Hospitals & Clinics (60%), Ambulatory Surgery Centers (25%), and Home Care Settings (15%)
- By Designation: Directors (35%), Vice Presidents (27%), Managers (22%), and Other Designations (16%)
- By Region: North America (40%), Europe (25%), the Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)
Key players in the Topical Drug Delivery Market
The prominent players in the topical drug delivery market are Johnson & Johnson Private Limited (US), Galderma (Switzerland), Bayer AG (Germany), Novartis International AG (Switzerland), AbbVie Inc. (US), GSK Plc. (UK), Bausch Health Companies Inc. (Canada), Glenmark Pharmaceuticals Ltd. (India), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Boehringer Ingelheim International GmbH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Viatris Inc. (US), Organon group of companies (US), Solventum (US), Crescita Therapeutics Inc. (Canada), Luye Pharma Group (China), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Rusan Pharma Ltd. (India), and AdhexPharma (France).
Research Coverage:
The report analyzes the topical drug delivery market. It aims to estimate the market size and future growth potential of this market based on various segments such as product, site of application, end user, and region. The report also includes a product portfolio matrix of various topical drug delivery products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which in turn would help them garner a more significant share of the market. Firms purchasing the report could use one or any combination of the following strategies to strengthen their position in the market.
This report provides insights into the following pointers:
- Market Penetration: Comprehensive information on product portfolios offered by the top players in the topical drug delivery market. The report analyzes this market by product, site of application, and end users.
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the topical drug delivery market
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various topical drug delivery products across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the topical drug delivery market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the topical drug delivery market.
Table of Contents
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS & EXCLUSIONS 36
1.2.2 MARKETS & REGIONS COVERED 37
1.2.3 YEARS CONSIDERED 38
1.2.4 CURRENCY CONSIDERED 38
1.3 MARKET STAKEHOLDERS 39
1.4 LIMITATIONS 39
1.5 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
2.2 RESEARCH METHODOLOGY DESIGN 41
2.2.1 SECONDARY DATA 42
2.2.1.1 Key data from secondary sources 43
2.2.2 PRIMARY DATA 43
2.2.2.1 Key data from primary sources 45
2.2.2.2 Key industry insights 45
2.3 MARKET SIZE ESTIMATION 47
2.3.1 APPROACH 1: REVENUE SHARE ANALYSIS 47
2.3.2 APPROACH 2: PHARMACEUTICAL SALES ANALYSIS 49
2.3.3 APPROACH 3: TOP-DOWN APPROACH 50
2.3.4 APPROACH 4: BOTTOM-UP APPROACH 50
2.3.5 APPROACH 4: PRIMARY INTERVIEWS 51
2.3.6 APPROACH 5: DEMAND-SIDE APPROACH 51
2.3.7 APPROACH 6: VOLUME DATA ANALYSIS 52
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 55
2.5 MARKET SHARE ANALYSIS 56
2.6 STUDY ASSUMPTIONS 56
2.6.1 GROWTH RATE ASSUMPTIONS 56
2.7 RISK ASSESSMENT 57
2.8 LIMITATIONS 57
2.8.1 METHODOLOGY-RELATED LIMITATIONS 57
2.8.2 SCOPE-RELATED LIMITATIONS 57
3 EXECUTIVE SUMMARY 58
4 PREMIUM INSIGHTS 61
4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW 61
4.2 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT & COUNTRY (2024) 62
4.3 TOPICAL DRUG DELIVERY MARKET: REGIONAL MIX 63
4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 64
5 MARKET OVERVIEW 65
5.1 INTRODUCTION 65
5.2 MARKET DYNAMICS 66
5.2.1 DRIVERS 66
5.2.1.1 Increasing prevalence of skin disorders 66
5.2.1.2 High incidence of burn injuries 67
5.2.1.3 Growing emphasis on patient convenience 68
5.2.1.4 Increasing investments in pharmaceutical R&D 69
5.2.1.5 Rising incidence of chronic diseases 70
5.2.2 RESTRAINTS 71
5.2.2.1 Adverse skin reactions & allergies 71
5.2.2.2 Drug failure & recalls of TDD systems 71
5.2.2.3 High development costs of topical drug delivery products 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Growing preference for self-administration and home care 73
5.2.3.2 High growth potential of emerging economies 73
5.2.4 CHALLENGES 74
5.2.4.1 Technical barriers related to skin irritation & permeability 74
5.3 INDUSTRY TRENDS 75
5.3.1 ADVANCES IN TRANSDERMAL DRUG DELIVERY SYSTEMS 75
5.3.2 EMERGENCE OF MICRONEEDLE PATCH TECHNOLOGIES 76
5.4 TECHNOLOGY ANALYSIS 77
5.4.1 KEY TECHNOLOGIES 77
5.4.1.1 Nanocarrier-based delivery systems 77
5.4.1.2 Microemulsions & nanoemulsion 77
5.4.1.3 Thermosensitive & pH-sensitive hydrogels & hydrocolloids 78
5.4.2 COMPLEMENTARY TECHNOLOGIES 79
5.4.2.1 Microneedle-enhanced delivery 79
5.4.2.2 AI-assisted formulations & prediction models 79
5.4.3 ADJACENT TECHNOLOGIES 80
5.4.3.1 Wearable sensor-integrated topical patches 80
5.4.3.2 3D testing skin models 80
5.5 PORTER’S FIVE FORCES ANALYSIS 81
5.5.1 THREAT OF NEW ENTRANTS 82
5.5.2 THREAT OF SUBSTITUTES 83
5.5.3 BARGAINING POWER OF SUPPLIERS 83
5.5.4 BARGAINING POWER OF BUYERS 83
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 83
5.6 REGULATORY LANDSCAPE 84
5.6.1 REGULATORY ANALYSIS 84
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
5.7 PATENT ANALYSIS 88
5.7.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY 88
5.7.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS 89
5.8 TRADE ANALYSIS 90
5.8.1 TRADE DATA FOR HS CODE 300490 90
5.8.1.1 Import data for HS Code 300490 90
5.8.1.2 Export data for HS Code 300490 91
5.9 PRICING ANALYSIS 91
5.9.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022−2024 92
5.9.2 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024 93
5.9.3 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024 93
5.9.4 AVERAGE SELLING PRICE, BY REGION 94
5.9.5 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024 94
5.9.5.1 Average selling price trend of ointments, by region, 2022−2024 95
5.9.5.2 Average selling price trend of creams, by region, 2022−2024 95
5.9.5.3 Average selling price trend of gels, by region, 2022−2024 95
5.10 REIMBURSEMENT ANALYSIS 95
5.11 KEY CONFERENCES & EVENTS, 2025–2026 97
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 99
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 99
5.12.2 BUYING CRITERIA 99
5.13 UNMET NEEDS/END-USER EXPECTATIONS 101
5.14 IMPACT OF AI ON TOPICAL DRUG DELIVERY MARKET 102
5.14.1 AI-USE CASES 103
5.15 PIPELINE ANALYSIS 103
5.16 ECOSYSTEM MARKET MAP 105
5.17 VALUE CHAIN ANALYSIS 106
5.18 INVESTMENT & FUNDING SCENARIO 108
5.19 TRUMP TARIFF IMPACT ON TOPICAL DRUG DELIVERY MARKET 109
5.19.1 INTRODUCTION 109
5.19.2 KEY TARIFF RATES 110
5.19.3 PRICE IMPACT ANALYSIS 111
5.19.4 KEY IMPACT ON VARIOUS REGIONS 111
5.19.5 END-USE INDUSTRY IMPACT 113
6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT 115
6.1 INTRODUCTION 116
6.2 SEMI-SOLID FORMULATIONS 117
6.2.1 OINTMENTS 121
6.2.1.1 Wide applications in analgesic indications to drive market 121
6.2.2 CREAMS 124
6.2.2.1 High absorption capabilities to boost demand 124
6.2.3 LOTIONS 127
6.2.3.1 Convenient application to fuel uptake 127
6.2.4 GELS 129
6.2.4.1 Enhanced patient compliance and aesthetic appeal to drive market 129
6.2.5 PASTES 132
6.2.5.1 Prevention of skin irritation to fuel uptake 132
6.3 LIQUID FORMULATIONS 133
6.3.1 SUSPENSIONS 136
6.3.1.1 Higher rate of bioavailability and controlled onset of action to drive market 136
6.3.2 EMULSIONS 138
6.3.2.1 Versatile carriers for enhanced drug delivery to fuel uptake 138
6.3.3 SOLUTIONS 140
6.3.3.1 Uniform & rapid drug delivery to boost demand 140
6.4 SOLID FORMULATIONS 142
6.4.1 POWDERS 144
6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel market 144
6.4.2 SUPPOSITORIES 146
6.4.2.1 Ability to ensure drug compatibility to fuel market 146
6.4.3 FILM 148
6.4.3.1 Next-generation advancements to boost demand 148
6.5 TRANSDERMAL PRODUCTS 150
6.5.1 TRANSDERMAL PATCHES 152
6.5.1.1 Drug-in-adhesive patches 156
6.5.1.1.1 Enhanced drug release to fuel uptake 156
6.5.1.2 Matrix patches 157
6.5.1.2.1 Rising technological advancements to boost demand 157
6.5.1.3 Reservoir membrane patches 159
6.5.1.3.1 Prolonged drug delivery to fuel market 159
6.5.1.4 Microneedle patches 161
6.5.1.4.1 Ability to deliver APIs to support market growth 161
6.5.1.5 Iontophoresis patches 162
6.5.1.5.1 Low molecular weight patches to support market growth 162
6.5.1.6 Vapor patches 164
6.5.1.6.1 Ability to release essential oils to support market growth 164
6.5.2 TRANSDERMAL GELS 166
6.5.2.1 Rapid release of drugs to fuel uptake 166
6.5.3 TRANSDERMAL SPRAYS 168
6.5.3.1 Targeted approach to boost demand 168
6.6 OTHER PRODUCTS 169
7 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION 172
7.1 INTRODUCTION 173
7.2 DERMAL DRUG DELIVERY 173
7.2.1 STANDARD MEDIUM WITH HIGH DRUG ABSORPTION TO PROPEL MARKET 173
7.3 OPHTHALMIC DRUG DELIVERY 176
7.3.1 FOCUS ON MICROEMULSION-BASED FORMULATIONS TO BOOST DEMAND 176
7.4 VAGINAL DRUG DELIVERY 179
7.4.1 LIMITED INTERVENTION BY MEDICAL PERSONNEL TO DRIVE MARKET 179
7.5 RECTAL DRUG DELIVERY 181
7.5.1 COMBINATION OF LOCAL & SYSTEMIC THERAPY OF DRUGS TO FUEL UPTAKE 181
7.6 NASAL DRUG DELIVERY 182
7.6.1 QUICK ONSET OF DRUG ACTION & CONVENIENCE TO SUPPORT MARKET UPTAKE 182
8 TOPICAL DRUG DELIVERY MARKET, BY END USER 185
8.1 INTRODUCTION 186
8.2 HOME CARE SETTINGS 186
8.2.1 HIGH PREFERENCE, AFFORDABILITY, AND CONVENIENCE TO PROPEL MARKET 186
8.3 HOSPITALS & CLINICS 189
8.3.1 ADOPTION OF TOPICAL ANAESTHETICS FOR MEDICAL & SURGICAL SUB-SPECIALTIES TO DRIVE MARKET 189
8.4 AMBULATORY SURGERY CENTERS 191
8.4.1 UTILIZATION OF ANTIMICROBIAL TOPICAL DRUGS FOR TRAUMA CASES TO BOOST DEMAND 191
8.5 BURN CARE CENTERS 193
8.5.1 HIGH INCIDENCE OF BURN INJURIES AND UPTAKE OF OINTMENTS TO SUPPORT MARKET GROWTH 193
8.6 OTHER END USERS 194
9 TOPICAL DRUG DELIVERY MARKET, BY REGION 196
9.1 INTRODUCTION 197
9.2 NORTH AMERICA 198
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 199
9.2.2 US 203
9.2.2.1 Rising prevalence of skin diseases to drive market 203
9.2.3 CANADA 207
9.2.3.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth 207
9.3 EUROPE 211
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 212
9.3.2 GERMANY 216
9.3.2.1 Growing focus of R&D for pharmaceutical API development to boost demand 216
9.3.3 UK 220
9.3.3.1 Rising demand for painless treatment alternatives to fuel market 220
9.3.4 FRANCE 224
9.3.4.1 Rising incidence of diabetes and subsequent increase in skin lesions to drive market 224
9.3.5 ITALY 228
9.3.5.1 Rising demand for transdermal patches to propel market 228
9.3.6 SPAIN 232
9.3.6.1 Expanding research hub to fuel market 232
9.3.7 NETHERLANDS 236
9.3.7.1 Public awareness initiatives for preventive care to fuel uptake 236
9.3.8 REST OF EUROPE 240
9.4 ASIA PACIFIC 244
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 245
9.4.2 CHINA 250
9.4.2.1 Rising cases of communicable diseases to drive market 250
9.4.3 JAPAN 254
9.4.3.1 Increasing number of product approvals to drive market 254
9.4.4 INDIA 258
9.4.4.1 Growing focus on adoption of non-invasive drug delivery methods to drive market 258
9.4.5 AUSTRALIA 262
9.4.5.1 Increasing number of smokers to fuel uptake 262
9.4.6 SOUTH KOREA 266
9.4.6.1 Favorable government focus on expanding clinical trials to boost demand 266
9.4.7 THAILAND 270
9.4.7.1 Regulatory reforms and supportive healthcare initiatives to support market growth 270
9.4.8 VIETNAM 274
9.4.8.1 Increasing investments and regulatory reforms to fuel uptake 274
9.4.9 REST OF ASIA PACIFIC 278
9.5 LATIN AMERICA 282
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 282
9.5.2 BRAZIL 286
9.5.2.1 High prevalence of diabetes to propel market growth 286
9.5.3 MEXICO 290
9.5.3.1 Increasing prevalence of glaucoma to drive market 290
9.5.4 REST OF LATIN AMERICA 294
9.6 MIDDLE EAST & AFRICA 298
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 299
9.6.2 GCC COUNTRIES 302
9.6.2.1 Kingdom of Saudi Arabia (KSA) 306
9.6.2.1.1 Expanding healthcare infrastructure to boost demand 306
9.6.2.2 United Arab Emirates (UAE) 310
9.6.2.2.1 Increasing prevalence of diabetes to fuel uptake 310
9.6.2.3 Other GCC Countries 314
9.6.3 REST OF MIDDLE EAST & AFRICA 318
10 COMPETITIVE LANDSCAPE 323
10.1 OVERVIEW 323
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 323
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET 324
10.3 REVENUE ANALYSIS, 2020–2024 326
10.4 MARKET SHARE ANALYSIS 326
10.4.1 RANKING OF KEY MARKET PLAYERS 329
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 329
10.5.1 STARS 329
10.5.2 EMERGING LEADERS 330
10.5.3 PERVASIVE PLAYERS 330
10.5.4 PARTICIPANTS 330
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 331
10.5.5.1 Company footprint 331
10.5.5.2 Region footprint 332
10.5.5.3 Product footprint 333
10.5.5.4 Site of application footprint 334
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 335
10.6.1 PROGRESSIVE COMPANIES 335
10.6.2 RESPONSIVE COMPANIES 335
10.6.3 DYNAMIC COMPANIES 335
10.6.4 STARTING BLOCKS 335
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 337
10.6.5.1 Detailed list of key startups/SME players 337
10.6.5.2 Competitive benchmarking of key emerging players/startups 337
10.7 BRAND/PRODUCT COMPARISON 338
10.7.1 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 338
10.8 R&D EXPENDITURE OF KEY PLAYERS 339
10.8.1 R&D EXPENDITURE OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET 339
10.9 COMPANY VALUATION & FINANCIAL METRICS 339
10.9.1 FINANCIAL METRICS 339
10.9.2 COMPANY VALUATION 340
10.10 COMPETITIVE SCENARIO 340
10.10.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS 340
10.10.2 DEALS 341
10.10.3 EXPANSIONS 342
10.10.4 OTHER DEVELOPMENTS 344
11 COMPANY PROFILES 345
11.1 KEY PLAYERS 345
11.1.1 JOHNSON & JOHNSON SERVICES, INC. 345
11.1.1.1 Business overview 345
11.1.1.2 Products offered 346
11.1.1.3 Recent developments 347
11.1.1.3.1 Product approvals 347
11.1.1.3.2 Deals 348
11.1.1.4 MnM view 348
11.1.1.4.1 Key strengths 348
11.1.1.4.2 Strategic choices 348
11.1.1.4.3 Weaknesses & competitive threats 348
11.1.2 GALDERMA 349
11.1.2.1 Business overview 349
11.1.2.2 Products offered 350
11.1.2.3 Recent developments 351
11.1.2.3.1 Product launches & approvals 351
11.1.2.3.2 Deals 352
11.1.2.3.3 Expansions 352
11.1.2.4 MnM view 353
11.1.2.4.1 Key strengths 353
11.1.2.4.2 Strategic choices 353
11.1.2.4.3 Weaknesses & competitive threats 353
11.1.3 BAYER AG 354
11.1.3.1 Business overview 354
11.1.3.2 Products offered 355
11.1.3.3 Recent developments 356
11.1.3.3.1 Product launches & approvals 356
11.1.3.3.2 Deals 356
11.1.3.4 MnM view 357
11.1.3.4.1 Key strengths 357
11.1.3.4.2 Strategic choices 357
11.1.3.4.3 Weaknesses & competitive threats 357
11.1.4 NOVARTIS AG 358
11.1.4.1 Business overview 358
11.1.4.2 Products offered 359
11.1.4.3 Recent developments 360
11.1.4.3.1 Deals 360
11.1.4.3.2 Other developments 360
11.1.4.4 MnM view 361
11.1.4.4.1 Key strengths 361
11.1.4.4.2 Strategic choices 361
11.1.4.4.3 Weaknesses & competitive threats 361
11.1.5 ABBVIE INC. 362
11.1.5.1 Business overview 362
11.1.5.2 Products offered 363
11.1.5.3 Recent developments 364
11.1.5.3.1 Product launches 364
11.1.5.3.2 Expansions 365
11.1.5.3.3 Other developments 365
11.1.5.4 MnM view 365
11.1.5.4.1 Key strengths 365
11.1.5.4.2 Strategic choices 366
11.1.5.4.3 Weaknesses & competitive threats 366
11.1.6 GLENMARK PHARMACEUTICALS LIMITED 367
11.1.6.1 Business overview 367
11.1.6.2 Products offered 368
11.1.6.3 Recent developments 370
11.1.6.3.1 Product approvals 370
11.1.6.3.2 Deals 373
11.1.7 GSK PLC. 374
11.1.7.1 Business overview 374
11.1.7.2 Products offered 375
11.1.7.3 Recent developments 376
11.1.7.3.1 Deals 376
11.1.7.3.2 Other developments 377
11.1.8 BAUSCH HEALTH COMPANIES INC. 378
11.1.8.1 Business overview 378
11.1.8.2 Products offered 379
11.1.8.3 Recent developments 381
11.1.8.3.1 Product launches & approvals 381
11.1.8.3.2 Deals 382
11.1.9 HISAMITSU PHARMACEUTICAL CO., INC. 383
11.1.9.1 Business overview 383
11.1.9.2 Products offered 384
11.1.9.3 Recent developments 385
11.1.9.3.1 Product launches, enhancements, and approvals 385
11.1.9.3.2 Deals 386
11.1.9.3.3 Expansions 386
11.1.10 CIPLA 387
11.1.10.1 Business overview 387
11.1.10.2 Products offered 388
11.1.10.3 Recent developments 391
11.1.10.3.1 Deals 391
11.1.11 VIATRIS INC. 392
11.1.11.1 Business overview 392
11.1.11.2 Products offered 393
11.1.11.3 Recent developments 395
11.1.11.3.1 Product launches & approvals 395
11.1.11.3.2 Deals 396
11.1.11.3.3 Other developments 396
11.1.12 ORGANON GROUP OF COMPANIES 397
11.1.12.1 Business overview 397
11.1.12.2 Products offered 398
11.1.12.3 Recent developments 399
11.1.12.3.1 Product approvals 399
11.1.12.3.2 Deals 399
11.1.13 PFIZER, INC. 400
11.1.13.1 Business overview 400
11.1.13.2 Products offered 401
11.1.13.3 Recent developments 402
11.1.13.3.1 Product approvals 402
11.1.13.3.2 Deals 402
11.1.14 CRESCITA THERAPEUTICS INC. 403
11.1.14.1 Business overview 403
11.1.14.2 Products offered 404
11.1.14.3 Recent developments 405
11.1.14.3.1 Deals 405
11.1.14.3.2 Other developments 405
11.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 406
11.1.15.1 Business overview 406
11.1.15.2 Products offered 407
11.1.15.3 Recent developments 408
11.1.15.3.1 Deals 408
11.1.15.3.2 Expansions 408
11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. 409
11.1.16.1 Business overview 409
11.1.16.2 Products offered 410
11.1.16.3 Recent developments 411
11.1.16.3.1 Deals 411
11.1.17 SOLVENTUM 412
11.1.17.1 Business overview 412
11.1.17.2 Products offered 413
11.1.17.3 Recent developments 414
11.1.17.3.1 Deals 414
11.1.18 LUYE PHARMA GROUP 415
11.1.18.1 Business overview 415
11.1.18.2 Products offered 416
11.1.18.3 Recent developments 417
11.1.18.3.1 Product approvals 417
11.1.18.3.2 Deals 417
11.1.19 LEAD CHEMICAL CO., LTD. 418
11.1.19.1 Business overview 418
11.1.19.2 Products offered 418
11.1.20 PURDUE PHARMA L.P. 419
11.1.20.1 Business overview 419
11.1.20.2 Products offered 419
11.1.21 LAVIPHARM 420
11.1.21.1 Business overview 420
11.1.21.2 Products offered 421
11.2 OTHER PLAYERS 422
11.2.1 CMP PHARMA, INC. 422
11.2.2 ENCORE DERMATOLOGY, INC. 423
11.2.3 RUSAN PHARMA LTD. 424
11.2.4 ADHEXPHARMA 425
12 APPENDIX 426
12.1 DISCUSSION GUIDE 426
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 431
12.3 RELATED REPORTS 433
12.4 AUTHOR DETAILS 434
LIST OF TABLES
TABLE 1 STANDARD CURRENCY CONVERSION RATES (USD) 38
TABLE 2 TOPICAL DRUG DELIVERY MARKET: RISK ASSESSMENT ANALYSIS 57
TABLE 3 KEY DEVELOPMENTS FOR TRANSDERMAL DRUG DELIVERY SYSTEMS 76
TABLE 4 TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 82
TABLE 5 REGULATORY ADHERENCE FOR TOPICAL DRUG DELIVERY PRODUCTS, BY REGION 84
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 10 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 11 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 12 TOPICAL DRUG DELIVERY MARKET: MAJOR PATENTS 89
TABLE 13 IMPORT DATA FOR HS CODE 300490, BY COUNTRY,
2021–2024 (USD THOUSANDS) 90
TABLE 14 EXPORT DATA FOR HS CODE 300490, BY COUNTRY,
2021–2024 (USD THOUSANDS) 91
TABLE 15 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2022–2024 92
TABLE 16 AVERAGE SELLING PRICE TREND OF OINTMENTS, BY REGION, 2022–2024 95
TABLE 17 AVERAGE SELLING PRICE TREND FOR CREAMS, BY REGION, 2022–2024 95
TABLE 18 AVERAGE SELLING PRICE TREND OF GELS, BY REGION, 2022–2024 95
TABLE 19 TOPICAL DRUG DELIVERY MARKET: KEY CONFERENCES & EVENTS, 2025–2026 97
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS (%) 99
TABLE 21 KEY BUYING CRITERIA, BY END USER 100
TABLE 22 TOPICAL DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE (2024) 104
TABLE 23 TOPICAL DRUG DELIVERY PRODUCTS PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM 105
TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 110
TABLE 25 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR TOPICAL DRUG DELIVERY PRODUCTS 110
TABLE 26 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS 111
TABLE 27 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS 112
TABLE 28 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS 113
TABLE 29 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS 113
TABLE 30 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 117
TABLE 31 KEY PLAYERS OFFERING SEMI-SOLID FORMULATIONS 118
TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 119
TABLE 33 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 120
TABLE 34 KEY PLAYERS OFFERING OINTMENTS 121
TABLE 35 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY REGION,
2023–2030 (TEN THOUSAND UNITS) 122
TABLE 36 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY,
2023–2030 (USD BILLION) 123
TABLE 37 KEY PLAYERS OFFERING CREAMS 124
TABLE 38 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY REGION,
2023–2030 (TEN THOUSAND UNITS) 125
TABLE 39 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY,
2023–2030 (USD BILLION) 126
TABLE 40 KEY PLAYERS OFFERING LOTIONS 127
TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY,
2023–2030 (USD BILLION) 128
TABLE 42 KEY PLAYERS OFFERING GELS 129
TABLE 43 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY REGION,
2023–2030 (TEN THOUSAND UNITS) 130
TABLE 44 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY,
2023–2030 (USD BILLION) 131
TABLE 45 KEY PLAYERS OFFERING PASTES 132
TABLE 46 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY REGION,
2023–2030 (TEN THOUSAND UNITS) 132
TABLE 47 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY,
2023–2030 (USD BILLION) 133
TABLE 48 KEY PLAYERS OFFERING LIQUID FORMULATIONS 134
TABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE,
2023–2030 (USD BILLION) 134
TABLE 50 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 135
TABLE 51 KEY PLAYERS OFFERING SUSPENSIONS 136
TABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY,
2023–2030 (USD BILLION) 137
TABLE 53 KEY PLAYERS OFFERING EMULSIONS 138
TABLE 54 TOPICAL DRUG DELIVERY MARKET FOR EMULSIONS, BY COUNTRY,
2023–2030 (USD BILLION) 139
TABLE 55 KEY PLAYERS OFFERING SOLUTIONS 140
TABLE 56 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY,
2023–2030 (USD BILLION) 141
TABLE 57 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE,
2023–2030 (USD BILLION) 142
TABLE 58 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 143
TABLE 59 KEY PLAYERS OFFERING SOLID FORMULATIONS 144
TABLE 60 KEY PLAYERS OFFERING POWDERS 144
TABLE 61 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY,
2023–2030 (USD BILLION) 145
TABLE 62 KEY PLAYERS OFFERING SUPPOSITORIES 146
TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY,
2023–2030 (USD BILLION) 147
TABLE 64 KEY PLAYERS OFFERING FILM 148
TABLE 65 TOPICAL DRUG DELIVERY MARKET FOR FILM, BY COUNTRY,
2023–2030 (USD BILLION) 149
TABLE 66 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 150
TABLE 67 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2023–2030 (USD BILLION) 151
TABLE 68 KEY PLAYERS OFFERING TRANSDERMAL PRODUCTS 152
TABLE 69 KEY PLAYERS OFFERING TRANSDERMAL PATCHES 153
TABLE 70 TRANSDERMAL PATCHES MARKET, BY TYPE, 2023–2030 (USD BILLION) 153
TABLE 71 TRANSDERMAL PATCHES MARKET, BY REGION,
2023–2030 (TEN THOUSAND UNITS) 154
TABLE 72 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 155
TABLE 73 KEY PLAYERS OFFERING DRUG-IN-ADHESIVE PATCHES 156
TABLE 74 TRANSDERMAL DRUG-IN-ADHESIVE PATCHES MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 157
TABLE 75 KEY PLAYERS OFFERING MATRIX PATCHES 158
TABLE 76 TRANSDERMAL MATRIX PATCHES MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 158
TABLE 77 KEY PLAYERS OFFERING RESERVOIR MEMBRANE PATCHES 159
TABLE 78 TRANSDERMAL RESERVOIR MEMBRANE PATCHES MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 160
TABLE 79 KEY PLAYERS OFFERING MICRONEEDLE PATCHES 161
TABLE 80 TRANSDERMAL MICRONEEDLE PATCHES MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 162
TABLE 81 KEY PLAYERS OFFERING IONTOPHORESIS PATCHES 163
TABLE 82 TRANSDERMAL IONTOPHORESIS PATCHES MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 163
TABLE 83 KEY PLAYERS OFFERING VAPOR PATCHES 164
TABLE 84 TRANSDERMAL VAPOR PATCHES MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 165
TABLE 85 KEY PLAYERS OFFERING TRANSDERMAL GELS 166
TABLE 86 TRANSDERMAL GELS MARKET, BY REGION, 2023–2030 (TEN THOUSAND UNITS) 166
TABLE 87 TRANSDERMAL GELS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 167
TABLE 88 KEY PLAYERS OFFERING TRANSDERMAL SPRAYS 168
TABLE 89 TRANSDERMAL SPRAYS MARKET, BY REGION,
2023–2030 (TEN THOUSAND UNITS) 168
TABLE 90 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 169
TABLE 91 TOPICAL DRUG DELIVERY MARKET FOR OTHER PRODUCTS, BY COUNTRY,
2023–2030 (USD BILLION) 170
TABLE 92 KEY PLAYERS OFFERING OTHER PRODUCTS 171
TABLE 93 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 173
TABLE 94 KEY PLAYERS OFFERING DERMAL DRUG DELIVERY PRODUCTS 174
TABLE 95 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 175
TABLE 96 KEY PLAYERS OFFERING OPHTHALMIC DRUG DELIVERY PRODUCTS 177
TABLE 97 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 178
TABLE 98 KEY PLAYERS OFFERING VAGINAL DRUG DELIVERY PRODUCTS 179
TABLE 99 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 180
TABLE 100 KEY PLAYERS OFFERING RECTAL DRUG DELIVERY PRODUCTS 181
TABLE 101 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 182
TABLE 102 KEY PLAYERS OFFERING NASAL DRUG DELIVERY PRODUCTS 183
TABLE 103 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 184
TABLE 104 TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 186
TABLE 105 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION) 188
TABLE 106 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD BILLION) 190
TABLE 107 TOPICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS,
BY COUNTRY, 2023–2030 (USD BILLION) 192
TABLE 108 TOPICAL DRUG DELIVERY MARKET FOR BURN CARE CENTERS, BY COUNTRY, 2023–2030 (USD BILLION) 194
TABLE 109 TOPICAL DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY,
2023–2030 (USD BILLION) 195
TABLE 110 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION) 198
TABLE 111 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 200
TABLE 112 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 201
TABLE 113 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 201
TABLE 114 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 201
TABLE 115 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 202
TABLE 116 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 202
TABLE 117 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 202
TABLE 118 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 203
TABLE 119 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 203
TABLE 120 US: KEY MACROINDICATORS 204
TABLE 121 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 205
TABLE 122 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 205
TABLE 123 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 205
TABLE 124 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 206
TABLE 125 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 206
TABLE 126 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 206
TABLE 127 US: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 207
TABLE 128 US: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 207
TABLE 129 CANADA: KEY MACROINDICATORS 208
TABLE 130 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 208
TABLE 131 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 209
TABLE 132 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 209
TABLE 133 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 209
TABLE 134 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 210
TABLE 135 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 210
TABLE 136 CANADA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 211
TABLE 137 CANADA: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 211
TABLE 138 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 213
TABLE 139 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 213
TABLE 140 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 214
TABLE 141 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 214
TABLE 142 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 214
TABLE 143 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 215
TABLE 144 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 215
TABLE 145 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 216
TABLE 146 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 216
TABLE 147 GERMANY: KEY MACROINDICATORS 217
TABLE 148 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 218
TABLE 149 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 218
TABLE 150 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 218
TABLE 151 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 219
TABLE 152 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 219
TABLE 153 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 219
TABLE 154 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 220
TABLE 155 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 220
TABLE 156 UK: KEY MACROINDICATORS 221
TABLE 157 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 221
TABLE 158 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 222
TABLE 159 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 222
TABLE 160 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 222
TABLE 161 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 223
TABLE 162 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 223
TABLE 163 UK: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 224
TABLE 164 UK: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 224
TABLE 165 FRANCE: KEY MACROINDICATORS 225
TABLE 166 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 225
TABLE 167 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 226
TABLE 168 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 226
TABLE 169 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 226
TABLE 170 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 227
TABLE 171 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 227
TABLE 172 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 228
TABLE 173 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 228
TABLE 174 ITALY: KEY MACROINDICATORS 229
TABLE 175 ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 229
TABLE 176 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 230
TABLE 177 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 230
TABLE 178 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 230
TABLE 179 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 231
TABLE 180 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 231
TABLE 181 ITALY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 232
TABLE 182 ITALY: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 232
TABLE 183 SPAIN: KEY MACROINDICATORS 233
TABLE 184 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 233
TABLE 185 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 234
TABLE 186 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 234
TABLE 187 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 234
TABLE 188 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 235
TABLE 189 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 235
TABLE 190 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 236
TABLE 191 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 236
TABLE 192 NETHERLANDS: KEY MACROINDICATORS 237
TABLE 193 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 237
TABLE 194 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 238
TABLE 195 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 238
TABLE 196 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 238
TABLE 197 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 239
TABLE 198 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 239
TABLE 199 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 240
TABLE 200 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 240
TABLE 201 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 241
TABLE 202 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 241
TABLE 203 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 242
TABLE 204 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 242
TABLE 205 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 242
TABLE 206 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 243
TABLE 207 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 243
TABLE 208 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 244
TABLE 209 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 247
TABLE 210 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 247
TABLE 211 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 248
TABLE 212 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 248
TABLE 213 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 248
TABLE 214 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 249
TABLE 215 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 249
TABLE 216 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 250
TABLE 217 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 250
TABLE 218 CHINA: MACROECONOMIC INDICATORS 251
TABLE 219 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 251
TABLE 220 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 252
TABLE 221 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 252
TABLE 222 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 252
TABLE 223 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 253
TABLE 224 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 253
TABLE 225 CHINA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 254
TABLE 226 CHINA: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 254
TABLE 227 JAPAN: MACROECONOMIC INDICATORS 255
TABLE 228 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 256
TABLE 229 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 256
TABLE 230 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 256
TABLE 231 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 257
TABLE 232 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 257
TABLE 233 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 257
TABLE 234 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 258
TABLE 235 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 258
TABLE 236 INDIA: MACROECONOMIC INDICATORS 259
TABLE 237 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 260
TABLE 238 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 260
TABLE 239 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 260
TABLE 240 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 261
TABLE 241 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 261
TABLE 242 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 261
TABLE 243 INDIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 262
TABLE 244 INDIA: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 262
TABLE 245 AUSTRALIA: KEY MACROINDICATORS 263
TABLE 246 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 263
TABLE 247 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 264
TABLE 248 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 264
TABLE 249 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 264
TABLE 250 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 265
TABLE 251 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 265
TABLE 252 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 266
TABLE 253 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 266
TABLE 254 SOUTH KOREA: MACROECONOMIC INDICATORS 267
TABLE 255 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 267
TABLE 256 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 268
TABLE 257 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 268
TABLE 258 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 268
TABLE 259 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 269
TABLE 260 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 269
TABLE 261 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 270
TABLE 262 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 270
TABLE 263 THAILAND: MACROECONOMIC INDICATORS 271
TABLE 264 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 271
TABLE 265 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 272
TABLE 266 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 272
TABLE 267 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 272
TABLE 268 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 273
TABLE 269 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 273
TABLE 270 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 274
TABLE 271 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 274
TABLE 272 VIETNAM: MACROECONOMIC INDICATORS 275
TABLE 273 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 275
TABLE 274 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 276
TABLE 275 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 276
TABLE 276 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 276
TABLE 277 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 277
TABLE 278 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 277
TABLE 279 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 278
TABLE 280 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 278
TABLE 281 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 279
TABLE 282 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 279
TABLE 283 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 280
TABLE 284 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 280
TABLE 285 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 280
TABLE 286 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 281
TABLE 287 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 281
TABLE 288 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 282
TABLE 289 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 283
TABLE 290 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 283
TABLE 291 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 284
TABLE 292 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 284
TABLE 293 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 284
TABLE 294 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 285
TABLE 295 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 285
TABLE 296 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 286
TABLE 297 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 286
TABLE 298 BRAZIL: MACROECONOMIC INDICATORS 287
TABLE 299 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 287
TABLE 300 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 288
TABLE 301 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 288
TABLE 302 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 288
TABLE 303 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 289
TABLE 304 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 289
TABLE 305 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 290
TABLE 306 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 290
TABLE 307 MEXICO: MACROECONOMIC INDICATORS 291
TABLE 308 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 291
TABLE 309 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,
BY TYPE, 2023–2030 (USD BILLION) 292
TABLE 310 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 292
TABLE 311 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 292
TABLE 312 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,
BY TYPE, 2023–2030 (USD BILLION) 293
TABLE 313 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES,
BY TYPE, 2023–2030 (USD BILLION) 293
TABLE 314 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2023–2030 (USD BILLION) 294
TABLE 315 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 294
TABLE 316 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 295
TABLE 317 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 295
TABLE 318 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 295
TABLE 319 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 296
TABLE 320 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 296
TABLE 321 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 297
TABLE 322 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 297
TABLE 323 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 298
TABLE 324 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY REGION,
2023–2030 (USD BILLION) 299
TABLE 325 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 299
TABLE 326 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 300
TABLE 327 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 300
TABLE 328 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 300
TABLE 329 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 301
TABLE 330 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 301
TABLE 331 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 302
TABLE 332 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 302
TABLE 333 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY,
2023–2030 (USD BILLION) 303
TABLE 334 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 303
TABLE 335 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 304
TABLE 336 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 304
TABLE 337 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 304
TABLE 338 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 305
TABLE 339 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 305
TABLE 340 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 306
TABLE 341 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER,
2023–2030 (USD BILLION) 306
TABLE 342 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 307
TABLE 343 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 307
TABLE 344 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 308
TABLE 345 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 308
TABLE 346 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 308
TABLE 347 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 309
TABLE 348 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 309
TABLE 349 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 310
TABLE 350 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 310
TABLE 351 UNITED ARAB EMIRATES: KEY MACROINDICATORS 311
TABLE 352 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 311
TABLE 353 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 312
TABLE 354 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 312
TABLE 355 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 312
TABLE 356 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 313
TABLE 357 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 313
TABLE 358 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 314
TABLE 359 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 314
TABLE 360 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,
2023–2030 (USD BILLION) 315
TABLE 361 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 315
TABLE 362 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 316
TABLE 363 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 316
TABLE 364 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 316
TABLE 365 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 317
TABLE 366 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 317
TABLE 367 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 318
TABLE 368 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET,
BY PRODUCT, 2023–2030 (USD BILLION) 319
TABLE 369 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 319
TABLE 370 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 320
TABLE 371 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 320
TABLE 372 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 320
TABLE 373 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 321
TABLE 374 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 321
TABLE 375 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 322
TABLE 376 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET 324
TABLE 377 TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION 327
TABLE 378 TOPICAL DRUG DELIVERY MARKET: REGION FOOTPRINT 332
TABLE 379 TOPICAL DRUG DELIVERY MARKET: PRODUCT TYPE FOOTPRINT 333
TABLE 380 TOPICAL DRUG DELIVERY MARKET: SITE OF APPLICATION FOOTPRINT 334
TABLE 381 TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 337
TABLE 382 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 337
TABLE 383 TOPICAL DRUG DELIVERY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−JUNE 2025 340
TABLE 384 TOPICAL DRUG DELIVERY MARKET: DEALS, JANUARY 2022−JUNE 2025 341
TABLE 385 TOPICAL DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022–JUNE 2025 342
TABLE 386 TOPICAL DRUG DELIVERY MARKET: OTHERS, JANUARY 2022-JUNE 2025 344
TABLE 387 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 345
TABLE 388 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 346
TABLE 389 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS,
JANUARY 2022−JUNE 2025 347
TABLE 390 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022−JUNE 2025 348
TABLE 391 GALDERMA: COMPANY OVERVIEW 349
TABLE 392 GALDERMA: PRODUCTS OFFERED 350
TABLE 393 GALDERMA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 351
TABLE 394 GALDERMA: DEALS, JANUARY 2022–JUNE 2025 352
TABLE 395 GALDERMA: EXPANSIONS, JANUARY 2022–JUNE 2025 352
TABLE 396 BAYER AG: COMPANY OVERVIEW 354
TABLE 397 BAYER AG: PRODUCTS OFFERED 355
TABLE 398 BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 356
TABLE 399 BAYER AG: DEALS, JANUARY 2022–JUNE 2025 356
TABLE 400 NOVARTIS AG: COMPANY OVERVIEW 358
TABLE 401 NOVARTIS AG: PRODUCTS OFFERED 359
TABLE 402 NOVARTIS AG: DEALS, JANUARY 2022–JUNE 2025 360
TABLE 403 NOVARTIS AG: OTHERS, JANUARY 2022−JUNE 2025 360
TABLE 404 ABBVIE INC.: COMPANY OVERVIEW 362
TABLE 405 ABBVIE, INC.: PRODUCTS OFFERED 363
TABLE 406 ABBVIE INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025 364
TABLE 407 ABBVIE, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 365
TABLE 408 ABBVIE INC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025 365
TABLE 409 GLENMARK PHARMACEUTICALS LIMITED: COMPANY OVERVIEW 367
TABLE 410 GLENMARK PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 368
TABLE 411 GLENMARK PHARMACEUTICALS LIMITED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 370
TABLE 412 GLENMARK PHARMACEUTICALS LIMITED: DEALS, JANUARY 2022–JUNE 2025 373
TABLE 413 GSK PLC.: COMPANY OVERVIEW 374
TABLE 414 GSK PLC.: PRODUCTS OFFERED 375
TABLE 415 GSK PLC.: DEALS, JANUARY 2022–JUNE 2025 376
TABLE 416 GSK PLC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025 377
TABLE 417 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW 378
TABLE 418 BAUSCH HEALTH COMPANIES, INC.: PRODUCTS OFFERED 379
TABLE 419 BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–JUNE 2025 381
TABLE 420 BAUSCH HEALTH COMPANIES INC.: DEALS, JANUARY 2022–JUNE 2025 382
TABLE 421 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY OVERVIEW 383
TABLE 422 HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCTS OFFERED 384
TABLE 423 HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022–JUNE 2025 385
TABLE 424 HISAMITSU PHARMACEUTICAL CO., INC.: DEALS, JANUARY 2022–JUNE 2025 386
TABLE 425 HISAMITSU PHARMACEUTICAL CO., INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 386
TABLE 426 CIPLA: COMPANY OVERVIEW 387
TABLE 427 CIPLA: PRODUCTS OFFERED 388
TABLE 428 CIPLA: DEALS, JANUARY 2022–JUNE 2025 391
TABLE 429 VIATRIS INC.: COMPANY OVERVIEW 392
TABLE 430 VIATRIS INC.: PRODUCTS OFFERED 393
TABLE 431 VIATRIS INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 395
TABLE 432 VIATRIS INC.: DEALS, JANUARY 2022–JUNE 2025 396
TABLE 433 VIATRIS INC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025 396
TABLE 434 ORGANON GROUP OF COMPANIES: COMPANY OVERVIEW 397
TABLE 435 ORGANON GROUP OF COMPANIES: PRODUCTS OFFERED 398
TABLE 436 ORGANON GROUP OF COMPANIES: PRODUCT APPROVALS,
JANUARY 2022–JUNE 2025 399
TABLE 437 ORGANON GROUP OF COMPANIES: DEALS, JANUARY 2022–JUNE 2025 399
TABLE 438 PFIZER INC.: COMPANY OVERVIEW 400
TABLE 439 PFIZER INC.: PRODUCTS OFFERED 401
TABLE 440 PFIZER, INC.: PRODUCT APPROVALS, JANUARY 2022−JUNE 2025 402
TABLE 441 PFIZER, INC.: DEALS, JANUARY 2022−JUNE 2025 402
TABLE 442 CRESCITA THERAPEUTICS INC.: COMPANY OVERVIEW 403
TABLE 443 CRESCITA THERAPEUTICS INC.: PRODUCTS OFFERED 404
TABLE 444 CRESCITA THERAPEUTICS INC.: DEALS, JANUARY 2022–JUNE 2025 405
TABLE 445 CRESCITA THERAPEUTICS INC.: OTHER DEVELOPMENTS,
JANUARY 2022−JUNE 2025 405
TABLE 446 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 406
TABLE 447 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 407
TABLE 448 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS,
JANUARY 2022–JUNE 2025 408
TABLE 449 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS,
JANUARY 2022−APRIL 2025 408
TABLE 450 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 409
TABLE 451 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 410
TABLE 452 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022−JUNE 2025 411
TABLE 453 SOLVENTUM: COMPANY OVERVIEW 412
TABLE 454 SOLVENTUM: PRODUCTS OFFERED 413
TABLE 455 SOLVENTUM DEALS, JANUARY 2022–JUNE 2025 414
TABLE 456 LUYE PHARMA GROUP: COMPANY OVERVIEW 415
TABLE 457 LUYE PHARMA GROUP: PRODUCTS OFFERED 416
TABLE 458 LUYE PHARMA GROUP: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 417
TABLE 459 LUYE PHARMA GROUP: DEALS, JANUARY 2022−JUNE 2025 417
TABLE 460 LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW 418
TABLE 461 PURDUE PHARMA L.P.: COMPANY OVERVIEW 419
TABLE 462 PURDUE PHARMA L.P.: PRODUCTS OFFERED 419
TABLE 463 LAVIPHARM: COMPANY OVERVIEW 420
TABLE 464 LAVIPHARM: PRODUCTS OFFERED 421
TABLE 465 CMP PHARMA, INC.: COMPANY OVERVIEW 422
TABLE 466 ENCORE DERMATOLOGY, INC.: COMPANY OVERVIEW 423
TABLE 467 RUSAN PHARMA LTD.: COMPANY OVERVIEW 424
TABLE 468 ADHEXPHARMA: COMPANY OVERVIEW 425
LIST OF FIGURES
FIGURE 1 TOPICAL DRUG DELIVERY MARKET & REGIONAL SEGMENTATION 37
FIGURE 2 TOPICAL DRUG DELIVERY MARKET: RESEARCH DESIGN 41
FIGURE 3 PRIMARY SOURCES 44
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS 46
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 46
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 47
FIGURE 7 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 48
FIGURE 8 TOPICAL DRUG DELIVERY MARKET – REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON 48
FIGURE 9 REVENUE ANALYSIS OF TOP FIVE COMPANIES: TOPICAL DRUG DELIVERY MARKET (2024) 49
FIGURE 10 PHARMACEUTICAL SALES APPROACH 50
FIGURE 11 TOP-DOWN APPROACH 50
FIGURE 12 BOTTOM-UP APPROACH 51
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN TOPICAL DRUG DELIVERY MARKET (2025–2030): IMPACT ON MARKET GROWTH & CAGR) 53
FIGURE 14 CAGR PROJECTIONS 53
FIGURE 15 DATA TRIANGULATION METHODOLOGY 55
FIGURE 16 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION) 58
FIGURE 17 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION,
2025 VS. 2030 (USD BILLION) 59
FIGURE 18 TOPICAL DRUG DELIVERY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION) 59
FIGURE 19 GEOGRAPHIC SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET 60
FIGURE 20 INCREASING PREVALENCE OF SKIN DISORDERS AND RISING INCIDENCE OF BURN INJURIES TO PROPEL MARKET 61
FIGURE 21 SEMI-SOLID FORMULATIONS SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 62
FIGURE 22 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 63
FIGURE 23 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63
FIGURE 24 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 64
FIGURE 25 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66
FIGURE 26 BIOPHARMACEUTICAL R&D SPENDING (2020–2026) 69
FIGURE 27 TOP PHARMA R&D INVESTMENTS: LEADING COMPANY INVESTMENTS, 2023 69
FIGURE 28 TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 81
FIGURE 29 TOPICAL DRUG DELIVERY MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2014–JUNE 2025) 88
FIGURE 30 TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2014–JUNE 2025) 89
FIGURE 31 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024 93
FIGURE 32 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024 93
FIGURE 33 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024 94
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS 99
FIGURE 35 KEY BUYING CRITERIA FOR TOPICAL DRUG DELIVERY PRODUCTS, BY TOP THREE END USERS 100
FIGURE 36 AI-USE CASES 103
FIGURE 37 TOPICAL DRUG DELIVERY MARKET: ECOSYSTEM MAP 105
FIGURE 38 TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS 106
FIGURE 39 TOPICAL DRUG DELIVERY MARKET: INVESTMENT & FUNDING SCENARIO,
2020–2024 108
FIGURE 40 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 197
FIGURE 41 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 200
FIGURE 42 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 246
FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2022–2024 326
FIGURE 44 TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2024 327
FIGURE 45 RANKING OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2024 329
FIGURE 46 TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 330
FIGURE 47 TOPICAL DRUG DELIVERY MARKET: COMPANY FOOTPRINT 331
FIGURE 48 TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 336
FIGURE 49 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 338
FIGURE 50 R&D EXPENDITURE OF KEY PLAYERS, 2022–2024 339
FIGURE 51 EV/EBITDA OF KEY VENDORS 339
FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 340
FIGURE 53 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024) 346
FIGURE 54 GALDERMA: COMPANY SNAPSHOT (2024) 350
FIGURE 55 BAYER AG: COMPANY SNAPSHOT (2024) 355
FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT (2024) 359
FIGURE 57 ABBVIE, INC.: COMPANY SNAPSHOT (2024) 362
FIGURE 58 GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024) 367
FIGURE 59 GSK PLC.: COMPANY SNAPSHOT (2024) 375
FIGURE 60 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2024) 379
FIGURE 61 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2024) 383
FIGURE 62 CIPLA: COMPANY SNAPSHOT (2024) 388
FIGURE 63 VIATRIS INC.: COMPANY SNAPSHOT (2024) 393
FIGURE 64 ORGANON GROUP OF COMPANIES: COMPANY SNAPSHOT (2024) 398
FIGURE 65 PFIZER, INC.: COMPANY SNAPSHOT (2024) 401
FIGURE 66 CRESCITA THERAPEUTICS INC.: COMPANY SNAPSHOT (2024) 404
FIGURE 67 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024) 407
FIGURE 68 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024) 409
FIGURE 69 SOLVENTUM: COMPANY SNAPSHOT (2024) 413
FIGURE 70 LUYE PHARMA GROUP: COMPANY SNAPSHOT (2023) 416
FIGURE 71 COMPANY SNAPSHOT: LAVIPHARM (2024) 420
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11